Methylene Blue
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Methylene blue is a phenothiazine dye with a 130-year history in medicine — first synthesized as a textile dye in 1876, repurposed as the first synthetic antimalarial, then the foundational antibiotic precursor to chlorpromazine, and most durably established as the FDA-approved IV antidote for methemoglobinemia. The functional-medicine and longevity-biohacker community has reanimated interest in it as a low-oral-dose mitochondrial-respiration adjunct based on a 2008 cornerstone paper from Atamna’s group at the Children’s Hospital Oakland Research Institute ( 18187490) showing low-concentration methylene blue enhances Complex IV activity and cellular oxygen consumption.
The thing to hold from the start: methylene blue is a real drug with a real FDA-warned interaction class (serotonergic medications). Most peptides in this knowledge base have theoretical interaction concerns that get tiered with caveats. Methylene blue’s SSRI/SNRI/MAOI interaction is in a different category — it’s an FDA Drug Safety Communication, the mechanism is well-characterized (MAOI activity), and the documented adverse events have been life-threatening serotonin syndrome cases. If you’re on an SSRI, SNRI, MAOI, or other serotonergic drug, the answer for methylene blue is no — until you’re off it under your prescriber’s supervision. This is the one hard line in the article.
What does it do in my body?
Methylene blue’s mitochondrial mechanism is alternative-electron-carrier behavior in the electron transport chain (ETC). In normal mitochondrial respiration, electrons from NADH (and FADH2) flow sequentially through Complex I → Q → Complex III → cytochrome c → Complex IV → O₂ → water. When Complex I-III is dysfunctional — oxidative stress, age-related decline, certain neurodegenerative conditions — electrons “leak” upstream and reduce O₂ to superoxide (a reactive oxygen species, ROS) instead of completing the chain to water.
At low concentrations, methylene blue accepts electrons directly from NADH (and the upstream complexes) and donates them to cytochrome c, effectively bypassing the dysfunctional Complex I-III bottleneck. The downstream consequences:
- Fewer electrons leak upstream → fewer ROS produced
- More electrons reach their intended terminal acceptor (oxygen → water) → more ATP synthesized per glucose/fat molecule oxidized
- Reduced oxidative stress as a system-level outcome
- Enhanced Complex IV activity measured in cell-culture (Atamna 2008 reported ~30% Complex IV increase + 37-70% increase in cellular O₂ consumption at 0.5-4 µM in vitro)
The hormesis curve. Methylene blue’s effects are biphasic — low concentrations enhance mitochondrial respiration; high concentrations inhibit cytochrome c oxidase and become a net pro-oxidant. In the Atamna 2008 in-vitro data, the inflection is around 20 µM (above this, the mitochondrial benefit reverses into harm). The translation from in-vitro µM to in-vivo mg/kg dosing is where the data gets less clean — the community-cited “stay under ~5 mg/kg or pro-oxidant flip” threshold is extrapolation from in-vitro data, not a single-paper in-vivo human-dose number. The functional-medicine oral dose range (5-50 mg in adults daily) sits well below any plausible pro-oxidant inflection.
Why methylene blue gets bundled with the mitochondrial peptide cluster. MOTS-c activates AMPK and improves how the body uses energy; NAD+ (specifically NAD⁺) supplies the electron-carrier substrate the ETC needs; methylene blue corrects the ETC’s electron-flow efficiency itself. Three different levers on the same mitochondrial system. The decision-tree for which one fits a given user appears below.
How can it help me?
- Best fit: High oxidative-stress + mitochondrial-inefficiency profile; users with cognitive sluggishness who are NOT on serotonergic medications; the “support don’t push” alternative for burnt-out users who don’t tolerate NAD+
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Regulatory status: FDA-approved (high-dose IV) for methemoglobinemia — sold as Provayblue (methylene blue injection) and historically as generic methylene blue injection. Off-label oral use is widespread in the functional-medicine and biohacker community at the 5-50 mg/day range; this oral use is not FDA-approved but is not restricted either.
Pharmaceutical-grade oral methylene blue is available through:
- Compounding pharmacies (often as 5-10 mg lozenges or capsules; requires a prescription)
- Research-chemical vendors (USP-grade; available without prescription as research-use-only product, the same channel as most peptides discussed in this KB)
- Direct-to-consumer biohacker brands (Troscriptions / Trove “Just Blue” lozenges; BioVanish — quality varies, USP-grade verification matters)
Not a controlled substance. Not on the WADA prohibited list.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Form and dose. Pharmaceutical-grade methylene blue (USP-grade or pharmaceutical-grade — not industrial-grade, which contains heavy metals) is typically sold as a liquid concentrate (1% solution = 10 mg/mL) or as 5-10 mg lozenges or capsules. Functional-medicine practitioner range converges around 5-50 mg/day orally for cognitive / mitochondrial support.
- Lower-end (5-10 mg/day): typical starting dose. Often dosed once daily, AM.
- Mid-range (15-25 mg/day): common working dose for users targeting cognitive enhancement or mitochondrial-fatigue presentations.
- Higher-end (30-50 mg/day): the upper bound of the practitioner-camp range. Stay below if your goal is general support; the in-vitro pro-oxidant inflection is well above this in mg-equivalent terms but the human-dose mapping is extrapolated, so the practical ceiling holds.
Timing. Morning or mid-day. Methylene blue can be mildly activating; late-evening dosing may interfere with sleep onset.
The blue-pee question. Methylene blue stains urine blue or green (depending on dose and concurrent hydration). At higher doses it can also temporarily stain the sclera (whites of the eyes). Cosmetic only; not toxic; expected and harmless. Heads-up for users who don’t want surprise blue toilet water.
Source quality matters. Industrial-grade methylene blue (used for textile dyeing, aquarium treatments, lab staining) often contains heavy-metal contamination — chromium, arsenic, lead, mercury. USP-grade / pharmaceutical-grade is the only acceptable starting material for human use. This is the single most important sourcing check for methylene blue specifically.
Sequential testing vs the mitochondrial cluster (NAD+ / MOTS-c / methylene blue) — the decision tree. Each compound pushes a different lever on the same mitochondrial system, so stacking all three on day one creates “multiple layers of the same system pushed at once” — overstimulation, anxiety, paradoxical fatigue. Match the tool to the symptom presentation, give the system time to adapt (weeks, not days), then reassess before layering:
| Symptom presentation | What’s broken | First tool to trial |
|---|---|---|
| Feeling depleted, exhausted, cognitively slow, can’t recover | Low energy production — electron carrier substrate is depleted | NAD+ short-term |
| Feeling metabolically stuck, insulin-resistant, can’t adapt to stress or exercise (the perimenopausal “inner tube” pattern is a recurring example) | Inefficient energy use — AMPK signaling is depressed | MOTS-c |
| High oxidative stress + cognitive sluggishness + cumulative burnout + the patient who shouldn’t be “pressed harder on the gas” | Electron leakage + ROS upstream of ETC + Complex I-III bottleneck | Methylene blue |
for the decision-tree framing on top of the verified mechanism work. A useful practitioner-camp observation: methylene blue often eliminates the need for NAD+ in users whose primary issue is ETC inefficiency, because the alternative-carrier mechanism resolves the downstream energy-deficit symptoms without the new metabolic demand NAD+ adds. The two are not typically combined in functional-medicine practice — they pull on related levers and the combo creates the same “stacking the same system” problem.
What should I avoid combining — and what's synergistic?
Methylene Blue doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for Methylene Blue yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Drafted 2026-06-24 from + a verification pass on the chemistry, FDA serotonin-syndrome warning, in-vitro hormesis dose curve, and G6PD-deficiency contraindication. Methylene blue is a small-molecule pharmaceutical, not a peptide — it lives in this branch because it sits squarely in the mitochondrial-peptide adjunct cluster alongside MOTS-c, NAD+, SS-31 (Elamipretide), and Humanin & ARA-290 — the endogenous protection cluster. Cross-links: MOTS-c · NAD+ · SS-31 (Elamipretide) · Humanin & ARA-290 — the endogenous protection cluster · Peptides and SSRI Interactions: Risk Profile and Clinical Workflow · 5-Amino-1MQ.
| Class | Small-molecule phenothiazine; alternative-electron-carrier mitochondrial adjunct; reversible monoamine oxidase inhibitor (MAOI activity at clinical doses) |
| Mechanism (one line) | Donates electrons directly into the mitochondrial electron transport chain at cytochrome c, bypassing Complex I-III dysfunction → reduced electron leakage → fewer ROS upstream + improved ATP-production efficiency |
| FDA-approved indication | Methemoglobinemia (Provayblue IV) — well-established high-dose IV emergency use; this is the indication the FDA label covers |
| Off-label / functional-medicine use | Mitochondrial-respiration support; cognitive enhancement; oxidative-stress reduction. The low-oral-dose use case |
| Half-life | ~5 hours in plasma; metabolized primarily to leuco-methylene blue (the reduced active form) |
| Hard FDA-warned interaction | 🚨 Serotonin syndrome with SSRIs / SNRIs / MAOIs / TCAs / bupropion / buspirone / mirtazapine / venlafaxine / triptans / clomipramine / other serotonergic drugs — FDA Drug Safety Communication July 26, 2011 (updated October 20, 2011). Mechanism: methylene blue’s MAOI activity. This is the most important safety claim in the article — not a theoretical concern, an FDA-warned real interaction. |
| Hard contraindication | G6PD deficiency — risk of severe Heinz-body hemolytic anemia; on the FDA label as a contraindication |
| Cosmetic side effect | Stains urine blue-green and can stain the sclera (whites of the eyes) at higher doses. Reversible; cosmetic only, not toxic |
| Best-fit user | High oxidative-stress + mitochondrial-inefficiency profile; users with cognitive sluggishness who are NOT on serotonergic medications; the “support don’t push” alternative for burnt-out users who don’t tolerate NAD+ |
What it is
Methylene blue is a phenothiazine dye with a 130-year history in medicine — first synthesized as a textile dye in 1876, repurposed as the first synthetic antimalarial, then the foundational antibiotic precursor to chlorpromazine, and most durably established as the FDA-approved IV antidote for methemoglobinemia. The functional-medicine and longevity-biohacker community has reanimated interest in it as a low-oral-dose mitochondrial-respiration adjunct based on a 2008 cornerstone paper from Atamna’s group at the Children’s Hospital Oakland Research Institute ( 18187490) showing low-concentration methylene blue enhances Complex IV activity and cellular oxygen consumption.
The thing to hold from the start: methylene blue is a real drug with a real FDA-warned interaction class (serotonergic medications). Most peptides in this knowledge base have theoretical interaction concerns that get tiered with caveats. Methylene blue’s SSRI/SNRI/MAOI interaction is in a different category — it’s an FDA Drug Safety Communication, the mechanism is well-characterized (MAOI activity), and the documented adverse events have been life-threatening serotonin syndrome cases. If you’re on an SSRI, SNRI, MAOI, or other serotonergic drug, the answer for methylene blue is no — until you’re off it under your prescriber’s supervision. This is the one hard line in the article.
How it works
Methylene blue’s mitochondrial mechanism is alternative-electron-carrier behavior in the electron transport chain (ETC). In normal mitochondrial respiration, electrons from NADH (and FADH2) flow sequentially through Complex I → Q → Complex III → cytochrome c → Complex IV → O₂ → water. When Complex I-III is dysfunctional — oxidative stress, age-related decline, certain neurodegenerative conditions — electrons “leak” upstream and reduce O₂ to superoxide (a reactive oxygen species, ROS) instead of completing the chain to water.
At low concentrations, methylene blue accepts electrons directly from NADH (and the upstream complexes) and donates them to cytochrome c, effectively bypassing the dysfunctional Complex I-III bottleneck. The downstream consequences:
- Fewer electrons leak upstream → fewer ROS produced
- More electrons reach their intended terminal acceptor (oxygen → water) → more ATP synthesized per glucose/fat molecule oxidized
- Reduced oxidative stress as a system-level outcome
- Enhanced Complex IV activity measured in cell-culture (Atamna 2008 reported ~30% Complex IV increase + 37-70% increase in cellular O₂ consumption at 0.5-4 µM in vitro)
The hormesis curve. Methylene blue’s effects are biphasic — low concentrations enhance mitochondrial respiration; high concentrations inhibit cytochrome c oxidase and become a net pro-oxidant. In the Atamna 2008 in-vitro data, the inflection is around 20 µM (above this, the mitochondrial benefit reverses into harm). The translation from in-vitro µM to in-vivo mg/kg dosing is where the data gets less clean — the community-cited “stay under ~5 mg/kg or pro-oxidant flip” threshold is extrapolation from in-vitro data, not a single-paper in-vivo human-dose number. The functional-medicine oral dose range (5-50 mg in adults daily) sits well below any plausible pro-oxidant inflection.
Why methylene blue gets bundled with the mitochondrial peptide cluster. MOTS-c activates AMPK and improves how the body uses energy; NAD+ (specifically NAD⁺) supplies the electron-carrier substrate the ETC needs; methylene blue corrects the ETC’s electron-flow efficiency itself. Three different levers on the same mitochondrial system. The decision-tree for which one fits a given user appears below.
What the research shows
FDA-approved indication: methemoglobinemia. Methylene blue at 1-2 mg/kg IV is the standard antidote for acquired methemoglobinemia (where hemoglobin’s iron has been oxidized from Fe²⁺ to Fe³⁺, blocking O₂ transport). It works by donating electrons that reduce methemoglobin back to functional hemoglobin via the NADPH-dependent methemoglobin reductase pathway. This is the durable, decades-old FDA-approved use case (currently marketed as Provayblue).
Mitochondrial respiration enhancement (in-vitro).
- Atamna et al. 2008, FASEB J (PMID 18187490) — cornerstone hormesis paper. Low concentrations of methylene blue (0.5-4 µM) increased Complex IV activity ~30% and cellular O₂ consumption 37-70% in IMR90 fibroblasts; delayed cellular senescence markers. The pro-oxidant inflection was around 20 µM in the same assay.
- Atamna & Kumar 2010, J Alzheimers Dis — review applying the mitochondrial-respiration mechanism to Alzheimer’s-disease pathology.
Cognitive enhancement (animal + small human).
- Callaway, Riha, Bruchey, Munshi, Gonzalez-Lima 2004, Pharmacol Biochem Behav (PMID 14724055) — methylene blue improves brain oxidative metabolism and memory retention in rats; the foundational Gonzalez-Lima group paper.
- Gonzalez-Lima & Bruchey 2004, Learn Mem (PMID 15466319) — extinction-memory improvement via 4 mg/kg IP methylene blue in rats.
- Wrubel, Riha et al. 2007 (PMID 17428524) — discrimination-learning improvement in rats.
Alzheimer’s clinical trials (the leuco-methylene-blue line). TauRx Pharmaceuticals ran multi-year Phase 2 and Phase 3 trials of LMTX (a stabilized leuco-methylene blue prodrug) for Alzheimer’s disease, on the rationale that methylene blue inhibits tau-protein aggregation. The trials produced mixed-to-disappointing results — the LMTX Phase 3 (TRx-237-005, ~2016) did not show the predicted benefit as monotherapy. The honest read: the cognitive-enhancement signal in animal models hasn’t cleanly translated into Alzheimer’s-disease-modifying efficacy in humans, but the basic mitochondrial-respiration mechanism remains well-supported.
Where Western RCT evidence is thin: the low-oral-dose functional-medicine use case (5-50 mg daily for general cognitive support + oxidative-stress reduction) has minimal controlled human trial data. The mechanism is solid, the in-vitro work is consistent, the rodent cognition record is real, and decades of high-dose IV emergency use establish a clean acute-safety record — but the specific oral-low-dose-daily protocol most users actually run is anchored in mechanism + small case series + functional-medicine clinical experience, not Phase 3 RCT data.
Real-world protocol
Educational purposes only. Methylene blue is a prescription medication for methemoglobinemia (Provayblue IV) and is widely available off-label as both pharmaceutical-grade and research-chemical-grade oral product. This is not medical advice; the SSRI/SNRI/MAOI interaction below is a real FDA warning that requires prescriber awareness before use.
Form and dose. Pharmaceutical-grade methylene blue (USP-grade or pharmaceutical-grade — not industrial-grade, which contains heavy metals) is typically sold as a liquid concentrate (1% solution = 10 mg/mL) or as 5-10 mg lozenges or capsules. Functional-medicine practitioner range converges around 5-50 mg/day orally for cognitive / mitochondrial support.
- Lower-end (5-10 mg/day): typical starting dose. Often dosed once daily, AM.
- Mid-range (15-25 mg/day): common working dose for users targeting cognitive enhancement or mitochondrial-fatigue presentations.
- Higher-end (30-50 mg/day): the upper bound of the practitioner-camp range. Stay below if your goal is general support; the in-vitro pro-oxidant inflection is well above this in mg-equivalent terms but the human-dose mapping is extrapolated, so the practical ceiling holds.
Timing. Morning or mid-day. Methylene blue can be mildly activating; late-evening dosing may interfere with sleep onset.
The blue-pee question. Methylene blue stains urine blue or green (depending on dose and concurrent hydration). At higher doses it can also temporarily stain the sclera (whites of the eyes). Cosmetic only; not toxic; expected and harmless. Heads-up for users who don’t want surprise blue toilet water.
Source quality matters. Industrial-grade methylene blue (used for textile dyeing, aquarium treatments, lab staining) often contains heavy-metal contamination — chromium, arsenic, lead, mercury. USP-grade / pharmaceutical-grade is the only acceptable starting material for human use. This is the single most important sourcing check for methylene blue specifically.
Sequential testing vs the mitochondrial cluster (NAD+ / MOTS-c / methylene blue) — the decision tree. Each compound pushes a different lever on the same mitochondrial system, so stacking all three on day one creates “multiple layers of the same system pushed at once” — overstimulation, anxiety, paradoxical fatigue. Match the tool to the symptom presentation, give the system time to adapt (weeks, not days), then reassess before layering:
| Symptom presentation | What’s broken | First tool to trial |
|---|---|---|
| Feeling depleted, exhausted, cognitively slow, can’t recover | Low energy production — electron carrier substrate is depleted | NAD+ short-term |
| Feeling metabolically stuck, insulin-resistant, can’t adapt to stress or exercise (the perimenopausal “inner tube” pattern is a recurring example) | Inefficient energy use — AMPK signaling is depressed | MOTS-c |
| High oxidative stress + cognitive sluggishness + cumulative burnout + the patient who shouldn’t be “pressed harder on the gas” | Electron leakage + ROS upstream of ETC + Complex I-III bottleneck | Methylene blue |
for the decision-tree framing on top of the verified mechanism work. A useful practitioner-camp observation: methylene blue often eliminates the need for NAD+ in users whose primary issue is ETC inefficiency, because the alternative-carrier mechanism resolves the downstream energy-deficit symptoms without the new metabolic demand NAD+ adds. The two are not typically combined in functional-medicine practice — they pull on related levers and the combo creates the same “stacking the same system” problem.
Safety, side effects, and the FDA serotonin-syndrome warning
🚨 The hard line: methylene blue + serotonergic medications.
The FDA issued a Drug Safety Communication on July 26, 2011 (updated October 20, 2011), titled “Serious CNS Reactions Possible when Methylene Blue is Given to Patients Taking Certain Psychiatric Medications.” The communication followed multiple cases of life-threatening serotonin syndrome occurring when patients on serotonergic medications received methylene blue (most often as IV intraoperative methemoglobinemia treatment or parathyroid-surgery dye).
Mechanism: methylene blue is a potent reversible monoamine oxidase A (MAO-A) inhibitor at clinical doses. Combined with a serotonergic drug, it can drive synaptic serotonin to toxic levels → serotonin syndrome (hyperthermia, autonomic instability, neuromuscular excitation, altered mental status; can be fatal).
Drug classes flagged in the FDA communication:
- SSRIs (sertraline / Zoloft, escitalopram / Lexapro, fluoxetine / Prozac, paroxetine / Paxil, citalopram / Celexa, fluvoxamine, vilazodone, vortioxetine)
- SNRIs (duloxetine / Cymbalta, venlafaxine / Effexor, desvenlafaxine, levomilnacipran)
- Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline, clomipramine)
- MAO inhibitors (phenelzine, tranylcypromine, selegiline, isocarboxazid)
- Other serotonergic agents: bupropion (Wellbutrin), buspirone (Buspar), mirtazapine (Remeron), triptans (sumatriptan and class), tramadol, dextromethorphan, lithium, tryptophan, 5-HTP, St. John’s wort
The FDA documented adverse events occurred at IV doses of 1-8 mg/kg during parathyroid surgery. The FDA communication does NOT establish a “safe” low-dose oral threshold for use alongside serotonergic medications — the practical effect of the warning is that methylene blue should generally not be administered to patients on these drugs regardless of dose. Functional-medicine claims that sub-clinical oral doses are safe with SSRIs are not endorsed by the FDA, and given the case-report severity, the honest editorial position is: don’t.
OHM editorial position on this interaction: if you’re on an SSRI, SNRI, MAOI, TCA, or any of the other serotonergic drugs above, methylene blue is not the tool to add to your stack. The route forward is to taper off the serotonergic medication under your prescriber’s supervision first (weeks of washout depending on which drug), or pick a different mitochondrial adjunct (MOTS-c and NAD+ both have no documented serotonergic interaction; see Peptides and SSRI Interactions: Risk Profile and Clinical Workflow for the full peptide × SSRI framework). This is the one hard contraindication in this article and we’re saying it plainly because the case-report literature is real and severe.
G6PD deficiency — hard contraindication. Methylene blue is on the FDA label as contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of severe Heinz-body hemolytic anemia. Mechanism: methylene blue’s reduction to leuco-methylene blue (the active mitochondrial form) requires NADPH from the G6PD-dependent hexose monophosphate shunt; G6PD-deficient red cells can’t generate that NADPH, so (a) the drug doesn’t work for methemoglobinemia and (b) the oxidative stress triggers hemolysis. If you have known G6PD deficiency (most common in patients of Mediterranean, African, or Southeast Asian ancestry), methylene blue is off the table. (Source: PharmGKB pathway summary, PMC4091817; current Provayblue prescribing information.)
Mild side effects in routine use:
- Urine staining (blue-green) — expected, harmless, transient. Resolves within 24-48 hours of last dose.
- Sclera staining at higher doses — temporary, reversible, harmless.
- Mild GI upset with oral dosing — typically resolves; take with food.
- Mild headache or transient blood-pressure effects in some users — methylene blue affects nitric-oxide signaling at higher doses.
Pregnancy / breastfeeding: avoid. Not enough data; some animal data suggests teratogenic potential at high doses.
Drug-testing note: methylene blue is not typically screened on standard drug panels but its blue-pigment metabolites can theoretically interfere with colorimetric urine assays. If you’re a tested athlete or in a tested employment context, mention methylene blue use in advance.
Regulatory status
FDA-approved (high-dose IV) for methemoglobinemia — sold as Provayblue (methylene blue injection) and historically as generic methylene blue injection. Off-label oral use is widespread in the functional-medicine and biohacker community at the 5-50 mg/day range; this oral use is not FDA-approved but is not restricted either.
Pharmaceutical-grade oral methylene blue is available through:
- Compounding pharmacies (often as 5-10 mg lozenges or capsules; requires a prescription)
- Research-chemical vendors (USP-grade; available without prescription as research-use-only product, the same channel as most peptides discussed in this KB)
- Direct-to-consumer biohacker brands (Troscriptions / Trove “Just Blue” lozenges; BioVanish — quality varies, USP-grade verification matters)
Not a controlled substance. Not on the WADA prohibited list.
Cross-references
- MOTS-c — the mitochondrial-derived peptide that activates AMPK → improves energy utilization. The “metabolically stuck / insulin-resistant” first-pick in the decision tree above.
- NAD+ — the electron-carrier substrate. The “depleted / exhausted / can’t recover” first-pick. Methylene blue often substitutes for NAD+ in users whose primary issue is ETC inefficiency rather than NAD+ depletion (practitioner-camp observation; the two are rarely combined).
- SS-31 (Elamipretide) — cardiolipin-binding mitochondrial peptide that supports inner-membrane integrity. Complementary mechanism (membrane structure) to methylene blue’s electron-flow mechanism; could plausibly be stacked but Western evidence for the combo is absent.
- Humanin & ARA-290 — the endogenous protection cluster — mitochondrial-derived cytoprotective peptides; broader mitochondrial-cluster context.
- Peptides and SSRI Interactions: Risk Profile and Clinical Workflow — methylene blue belongs in this article’s hard-contraindication tier alongside Tesofensine. Both are FDA-warned interactions, not theoretical concerns.
- 5-Amino-1MQ — NNMT-inhibitor adjunct that preserves the NAD+ precursor pool. Different mechanism in the same cluster.
Technical & analytical reference (chemistry & QC)
Molecular identity verified against PubChem 2026-06-24.
| Field | Value |
|---|---|
| Molecular formula | C₁₆H₁₈ClN₃S (PubChem CID 6099) |
| Average MW | 319.85 g/mol |
| CAS | 61-73-4 |
| Class | Phenothiazine dye / small-molecule pharmaceutical; reversible MAO-A inhibitor at clinical doses; alternative-electron-carrier mitochondrial adjunct |
| IUPAC name | [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium chloride |
| Common synonyms | Methylene blue · methylthioninium chloride · MB · Basic Blue 9 |
| SMILES | CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.[Cl-] |
| Active in-vivo form | Leuco-methylene blue (reduced form) — generated by NADPH-dependent methemoglobin reductase + G6PD-dependent hexose-monophosphate-shunt pathway |
| Pharmaceutical-grade purity criterion | USP monograph ≥99% by HPLC; heavy metals screened to USP <231> (chromium, arsenic, lead, mercury — the dominant industrial-grade contamination concern) |
| Storage | Solid at room temp, dry, light-protected (methylene blue is photosensitive in solution); liquid solutions 2-8 °C |
| Hormesis dose curve (in-vitro) | Enhances Complex IV activity at 0.5-4 µM; inhibits cytochrome c oxidase + becomes net pro-oxidant above ~20 µM (Atamna 2008, PMID 18187490) |
| In-vivo pro-oxidant threshold | Community-cited ~5 mg/kg in vivo as the “stay under this” ceiling — extrapolation from in-vitro µM data, not a single-paper in-vivo number |
Sources
- Dr. Lara May 27:55 podcast episode 7 on mitochondrial peptides + the decision-tree framing for NAD+ vs MOTS-c vs methylene blue.
- PubChem CID 6099 (chemistry verification): https://pubchem.ncbi.nlm.nih.gov/compound/6099
- FDA Drug Safety Communication July 26, 2011 (updated October 20, 2011): “Serious CNS Reactions Possible when Methylene Blue is Given to Patients Taking Certain Psychiatric Medications” — original fda.gov URL is currently 404’d in FDA’s archive restructure; stable secondary mirror via the Anesthesia Patient Safety Foundation: https://www.apsf.org/article/methylene-blue-and-the-risk-of-serotonin-toxicity/
- Provayblue (methylene blue injection) prescribing information — current FDA label includes the serotonergic-drug warning and G6PD contraindication.
- Atamna et al. 2008, FASEB J (PMID 18187490) — cornerstone in-vitro hormesis paper showing Complex IV and cellular O₂-consumption enhancement at 0.5-4 µM.
- Callaway, Riha, Bruchey, Munshi, Gonzalez-Lima 2004, Pharmacol Biochem Behav (PMID 14724055) — foundational rodent brain-oxidative-metabolism + memory paper.
- Gonzalez-Lima & Bruchey 2004, Learn Mem (PMID 15466319) — extinction-memory improvement at 4 mg/kg IP in rats.
- Wrubel, Riha et al. 2007 (PMID 17428524) — discrimination-learning improvement.
- PharmGKB methylene blue pathway (G6PD-deficiency contraindication mechanism): https://pmc.ncbi.nlm.nih.gov/articles/PMC4091817/
Related: MOTS-c · NAD+ · SS-31 (Elamipretide) · Humanin & ARA-290 — the endogenous protection cluster · Peptides and SSRI Interactions: Risk Profile and Clinical Workflow · 5-Amino-1MQ.
Sources & references
- Dr. Lara May 27:55 podcast episode 7 on mitochondrial peptides + the decision-tree framing for NAD+ vs MOTS-c vs methylene blue.
- PubChem CID 6099 (chemistry verification): https://pubchem.ncbi.nlm.nih.gov/compound/6099
- FDA Drug Safety Communication July 26, 2011 (updated October 20, 2011): “Serious CNS Reactions Possible when Methylene Blue is Given to Patients Taking Certain Psychiatric Medications” — original fda.gov URL is currently 404’d in FDA’s archive restructure; stable secondary mirror via the Anesthesia Patient Safety Foundation: https://www.apsf.org/article/methylene-blue-and-the-risk-of-serotonin-toxicity/
- Provayblue (methylene blue injection) prescribing information — current FDA label includes the serotonergic-drug warning and G6PD contraindication.
- Atamna et al. 2008, FASEB J (PMID 18187490) — cornerstone in-vitro hormesis paper showing Complex IV and cellular O₂-consumption enhancement at 0.5-4 µM.
- Callaway, Riha, Bruchey, Munshi, Gonzalez-Lima 2004, Pharmacol Biochem Behav (PMID 14724055) — foundational rodent brain-oxidative-metabolism + memory paper.
- Gonzalez-Lima & Bruchey 2004, Learn Mem (PMID 15466319) — extinction-memory improvement at 4 mg/kg IP in rats.
- Wrubel, Riha et al. 2007 (PMID 17428524) — discrimination-learning improvement.
- PharmGKB methylene blue pathway (G6PD-deficiency contraindication mechanism): https://pmc.ncbi.nlm.nih.gov/articles/PMC4091817/
Related: MOTS-c · NAD+ · SS-31 (Elamipretide) · Humanin & ARA-290 — the endogenous protection cluster · Peptides and SSRI Interactions: Risk Profile and Clinical Workflow · 5-Amino-1MQ.